{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:43:48Z","timestamp":1793497428694,"version":"4.5.0"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease with a profound disease burden. In recent years, the advent of biologic therapies has improved the treatment landscape for patients with moderate to severe HS. In this new therapeutic era, the role of the general practitioner (GP) in HS treatment is becoming more important than ever. This review discusses how to recognize and diagnose HS by detailing common symptoms. HS can also present with multiple comorbidities. The GP\u2019s role in screening for and treating these important comorbidities is pivotal. This review highlights the HS treatment landscape, with a specific focus on what the GP can recommend. The three approved biologics for treating HS include adalimumab, secukinumab and bimekizumab; the benefits and concerns of biologics in everyday clinical practice are detailed. In summary, this review serves as a HS management guide for GPs, with a particular focus on the biologic treatment landscape.<\/jats:p>","DOI":"10.3389\/fmed.2024.1403455","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:30:14Z","timestamp":1720445414000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Biologic drugs in hidradenitis suppurativa: what does the GP have to know? A narrative review"],"prefix":"10.3389","volume":"11","author":[{"given":"Pedro","family":"Mendes-Bastos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farida","family":"Benhadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Molina-Levya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette","family":"Alarcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk G.","family":"Bechara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/jdv.18163","article-title":"Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US","volume":"36","author":"Ingram","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/postgradmedj-2013-131994","article-title":"Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease","volume":"90","author":"Dufour","year":"2014","journal-title":"Postgrad Med J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000431175","article-title":"Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation","volume":"231","author":"Zouboulis","year":"2015","journal-title":"Dermatology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Hidradenitis suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000508787","article-title":"Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system","volume":"236","author":"Kokolakis","year":"2020","journal-title":"Dermatology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/bjd.14038","article-title":"Diagnostic delay in hidradenitis suppurativa is a global problem","volume":"173","author":"Saunte","year":"2015","journal-title":"Br J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s40265-021-01566-2","article-title":"Clinical implementation of biologics and small molecules in the treatment of hidradenitis suppurativa","volume":"81","author":"Aarts","year":"2021","journal-title":"Drugs"},{"key":"ref10","article-title":"Novartis receives European approval for Cosentyx\u00ae as first and only IL-17a inhibitor for hidradenitis suppurativa 2023","year":""},{"key":"ref11","article-title":"FDA approves Novartis Cosentyx\u00ae as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade 2023","year":""},{"key":"ref12","article-title":"UCB receives European Commission approval for BIMZELX[\u00ae]\u25bc(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa 2024","year":""},{"key":"ref13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/exd.14338","article-title":"Target molecules for future hidradenitis suppurativa treatment","volume":"30","author":"Zouboulis","year":"2021","journal-title":"Exp Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/pharmaceutics14010044","article-title":"Hidradenitis suppurativa and comorbid disorder biomarkers, druggable genes, new drugs and drug repurposing-a molecular meta-analysis","volume":"14","author":"Zouboulis","year":"2021","journal-title":"Pharmaceutics"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"960488","DOI":"10.3389\/fimmu.2022.960488","article-title":"Innate immunity and microbial dysbiosis in hidradenitis suppurativa\u2014vicious cycle of chronic inflammation","volume":"13","author":"Chopra","year":"2022","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1001\/jamadermatol.2020.5467","article-title":"Global harmonization of morphological definitions in hidradenitis suppurativa for a proposed glossary","volume":"157","author":"Frew","year":"2021","journal-title":"JAMA Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1159\/000507348","article-title":"Proposed definitions of typical lesions in hidradenitis suppurativa","volume":"236","author":"Daxhelet","year":"2020","journal-title":"Dermatology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/bjd.18707","article-title":"Standing up together to the shame and stigma associated with hidradenitis suppurativa","volume":"182","author":"Kirby","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jid.2020.10.014","article-title":"Unraveling the heterogeneity of hidradenitis suppurativa with phenotype Schema","volume":"141","author":"Kirby","year":"2021","journal-title":"J Invest Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/jdv.16183","article-title":"Defining hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study","volume":"34","author":"Martorell","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","article-title":"Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian hidradenitis suppurativa foundations","volume":"86","author":"Garg","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/jamadermatol.2015.6264","article-title":"Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa","volume":"152","author":"Egeberg","year":"2016","journal-title":"JAMA Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jaad.2019.06.016","article-title":"All-cause mortality among patients with hidradenitis suppurativa: a population-based cohort study in the United States","volume":"81","author":"Reddy","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/ijd.15860","article-title":"Incidence, prevalence, and predictors of inflammatory arthritis in patients with hidradenitis suppurativa: a systematic review and meta-analysis","volume":"61","author":"Hanna","year":"2022","journal-title":"Int J Dermatol"},{"key":"ref27","article-title":"Is there a diet for hidradenitis suppurativa?","year":"2024"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/ijd.14697","article-title":"Prevalence of inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS): systematic review and adjusted meta-analysis","volume":"59","author":"Phan","year":"2020","journal-title":"Int J Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"15250","DOI":"10.3390\/ijms232315250","article-title":"The role of hormones in hidradenitis suppurativa: a systematic review","volume":"23","author":"Abu Rached","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.3390\/ijms24076596","article-title":"Screening for diabetes mellitus in patients with hidradenitis suppurativa\u2014a monocentric study in Germany","volume":"24","author":"Abu Rached","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.amjmed.2022.09.025","article-title":"A practical guide for primary care providers on timely diagnosis and comprehensive care strategies for hidradenitis suppurativa","volume":"136","author":"Garg","year":"2023","journal-title":"Am J Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"7240","DOI":"10.3390\/jcm11237240","article-title":"Current medical and surgical treatment of hidradenitis suppurativa\u2014a comprehensive review","volume":"11","author":"Ocker","year":"2022","journal-title":"J Clin Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/bjd.17695","article-title":"Inter-rater reliability of phenotypes and exploratory genotype-phenotype analysis in inherited hidradenitis suppurativa","volume":"181","author":"Frew","year":"2019","journal-title":"Br J Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jdermsci.2016.08.010","article-title":"Combination of oral zinc gluconate and topical triclosan: an anti-inflammatory treatment modality for initial hidradenitis suppurativa","volume":"84","author":"Hessam","year":"2016","journal-title":"J Dermatol Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/ddg.13563_g","article-title":"Laser hair removal alters the disease course in mild hidradenitis suppurativa","volume":"16","author":"Vossen","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity","volume":"161","author":"Sartorius","year":"2009","journal-title":"Br J Dermatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/ijd.14691","article-title":"Dietary and metabolic factors in the pathogenesis of hidradenitis suppurativa: a systematic review","volume":"59","author":"Choi","year":"2020","journal-title":"Int J Dermatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/bjd.18035","article-title":"A narrative review of the definition of 'flare' in hidradenitis suppurativa","volume":"182","author":"Kirby","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/bjd.21647","article-title":"International consensus definition of disease flare in hidradenitis suppurativa","volume":"187","author":"LeWitt","year":"2022","journal-title":"Br J Dermatol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/1346-8138.16275","article-title":"Effectiveness and safety of topical 15% resorcinol in the management of mild-to-moderate hidradenitis suppurativa: a cohort study","volume":"49","author":"Cordero-Ramos","year":"2022","journal-title":"J Dermatol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis suppurativa Foundations: part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/jdv.19810","article-title":"Deroofing: a safe, effective and well-tolerated procedure in patients with hidradenitis suppurativa","volume":"38","author":"Krajewski","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2S","DOI":"10.1177\/12034754221116115","article-title":"Practical guidelines for managing patients with hidradenitis suppurativa: an update","volume":"26","author":"Johnston","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/ijd.15459","article-title":"Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study","volume":"60","author":"J\u00f8rgensen","year":"2021","journal-title":"Int J Dermatol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12060978","article-title":"Systemic antibiotic therapy in hidradenitis suppurativa: a review on treatment landscape and current issues","volume":"12","author":"Molinelli","year":"2023","journal-title":"Antibiotics"},{"key":"ref47","article-title":"Humira summary of product characteristics","year":""},{"key":"ref48","article-title":"Cosentyx summary of product characteristics","year":""},{"key":"ref49","article-title":"Bimzelx summary of product characteristics","year":""},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e392","DOI":"10.1111\/jdv.18706","article-title":"Acitretin plus macrolides and acitretin monotherapy in the management of hidradenitis suppurativa","volume":"37","author":"Molinelli","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000526019","article-title":"Effectiveness and safety of Acitretin for the treatment of hidradenitis suppurativa, predictors of clinical response: a cohort study","volume":"239","author":"S\u00e1nchez-D\u00edaz","year":"2023","journal-title":"Dermatology"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jaad.2020.08.045","article-title":"Hidradenitis suppurativa in pediatric patients","volume":"86","author":"Choi","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.jid.2018.04.001","article-title":"Prevalence estimates for hidradenitis suppurativa among children and adolescents in the United States: a gender- and age-adjusted population analysis","volume":"138","author":"Garg","year":"2018","journal-title":"J Invest Dermatol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.3928\/19382359-20220222-02","article-title":"Diagnosing and managing hidradenitis suppurativa in pediatrics","volume":"51","author":"Collier","year":"2022","journal-title":"Pediatr Ann"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jdin.2020.05.005","article-title":"Hidradenitis suppurativa is an autoinflammatory keratinization disease: a review of the clinical, histologic, and molecular evidence","volume":"1","author":"Frew","year":"2020","journal-title":"JAAD Int"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e15803","DOI":"10.1111\/dth.15803","article-title":"Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?","volume":"35","author":"Roccuzzo","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"adv5278","DOI":"10.2340\/actadv.v103.5278","article-title":"Drug survival of anti interleukin-17 and interleukin-23 agents after adalimumab failure in hidradenitis suppurativa: a pilot study","volume":"103","author":"Repetto","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"ref60","article-title":"Lutikizumab showed positive results in a phase 2 trial of adults with moderate to severe hidradenitis suppurativa as program advances to phase 3 2024","year":""},{"key":"ref61","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jaad.2007.08.030","article-title":"From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis","volume":"58","author":"Lebwohl","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3390\/vaccines8040769","article-title":"Immune response to vaccination in patients with psoriasis treated with systemic therapies","volume":"8","author":"Chiricozzi","year":"2020","journal-title":"Vaccines"},{"key":"ref63","first-page":"249","article-title":"Vaccination recommendations for psoriasis and atopic dermatitis patients on biologic therapy: a practical guide","volume":"95","author":"Fan","year":"2022","journal-title":"Yale J Biol Med"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jaad.2019.03.017","article-title":"A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: from the Medical Board of the National Psoriasis Foundation","volume":"81","author":"Baumrin","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/rheumatology\/keh567","article-title":"TNF-blocking agents and tuberculosis: new drugs illuminate an old topic","volume":"44","author":"Keane","year":"2005","journal-title":"Rheumatology"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"100266","DOI":"10.1016\/j.lanepe.2021.100266","article-title":"Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sources","volume":"13","author":"Davidson","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"e14674","DOI":"10.1111\/dth.14674","article-title":"Pregnancy and breastfeeding in hidradenitis suppurativa: a review of medication safety","volume":"34","author":"Collier","year":"2021","journal-title":"Dermatol Ther"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"5894","DOI":"10.3390\/jcm10245894","article-title":"Impact of psoriasis and hidradenitis suppurativa in pregnancy, a systematic review","volume":"10","author":"Ferrer-Alcala","year":"2021","journal-title":"J Clin Med"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1111\/jdv.19238","article-title":"Exposure to biologic therapy before and during pregnancy in patients with psoriasis: systematic review and meta-analysis","volume":"37","author":"S\u00e1nchez-Garc\u00eda","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jaad.2016.10.032","article-title":"Management of hidradenitis suppurativa in pregnancy","volume":"76","author":"Perng","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","article-title":"Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial","volume":"156","author":"Bechara","year":"2021","journal-title":"JAMA Surg"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jaad.2016.06.014","article-title":"From the Medical Board of the National Psoriasis Foundation: perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis","volume":"75","author":"Choi","year":"2016","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1403455\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:30:18Z","timestamp":1720445418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1403455\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":72,"alternative-id":["10.3389\/fmed.2024.1403455"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1403455","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"article-number":"1403455"}}